Paediatrics, AJ Institute of Medical Sciences, Mangalore, India.
Medical Affairs and Clinical R&D, GSK Vaccines Europe, Wavre, Belgium.
Hum Vaccin Immunother. 2022 Dec 31;18(1):1-12. doi: 10.1080/21645515.2020.1866950. Epub 2021 Feb 18.
In India, the high neonatal and infant mortality rate is due in part to an increasing number of preterm and low birth weight (LBW) infants. Given the immaturity of immune system, these infants are at an increased risk of hospitalization and mortality from vaccine-preventable diseases (VPDs). In this narrative review, we screened the scientific literature for data on the risk of VPDs, vaccination delay and factors related to it in Indian preterm and LBW infants. Although routine childhood vaccinations are recommended regardless of gestational age or birth weight, vaccination is often delayed. It exposes these infants to a higher risk of infections, their associated complications, and death. After-birth complications, lack of awareness of recommendations, vaccine efficacy and effectiveness and concerns related to safety are some of the common barriers to vaccination. Awareness campaigns might help substantiate the need for (and value of) vaccination in preterm and LBW infants.
在印度,新生儿和婴儿死亡率居高不下,部分原因是早产儿和低出生体重儿(LBW)的数量不断增加。鉴于免疫系统不成熟,这些婴儿患疫苗可预防疾病(VPD)的住院和死亡风险更高。在这篇叙述性评论中,我们筛选了科学文献,以获取有关印度早产儿和 LBW 婴儿 VPD 风险、疫苗接种延迟及其相关因素的数据。尽管推荐无论胎龄或出生体重如何,都应进行常规儿童期疫苗接种,但疫苗接种往往会延迟。这使这些婴儿面临更高的感染风险、相关并发症和死亡风险。出生后并发症、对建议缺乏认识、疫苗的疗效和效果以及与安全性相关的担忧是疫苗接种的一些常见障碍。宣传活动可能有助于证实早产儿和 LBW 婴儿接种疫苗的必要性和价值。